Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT
Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256. Epub 2018 Apr 12.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 183828 | pLenti-EML4-ALK variant 1 | Express EML4-ALK fusion variant 1 (E13;A20) in mammalian cells |
| 183829 | pLenti-EML4-ALK variant 3a | Express EML4-ALK fusion variant 3a (E6a;A20) in mammalian cells |
| 183830 | pLenti-EML4-ALK variant 3a G1202R | Express EML4-ALK fusion variant 3a (E6a;A20) harboring ALK G1202R mutation in mammalian cells |
| 183831 | pLenti-EML4-ALK variant 3a L1196M/G1202R | Express EML4-ALK fusion variant 3a (E6a;A20) harboring ALK L1196M/G1202R mutation in mammalian cells |